Soluble ST2 as a Potential Biomarker in Pericardial Fluid of Coronary Artery Patients

Abstract

Introduction The growth Stimulation expressed gene 2 (ST2) (or interleukin 1 receptor-like 1, also known as IL1RL1) is considered a biomarker of poor prognosis in cardiovascular diseases. The aims of this study are to investigate ST2 in the pericardial fluid (PF) of coronary artery disease patients and to contribute to the understanding of the pathophysiology of coronary artery disease. Methods 40 patients (blood plasma and PF) who underwent coronary artery bypass surgery and 40 controls (blood plasma only) were included in this study. Soluble ST2 (sST2) level was determined by enzyme-linked ımmunosorbent assay method in plasma and PF, and sST2 gene expression was determined by quantitative real-time polymerase chain reaction (QRT-PCR) method. Results The sST2 level was found to be 44.89 ng/ml and 390.357 ng/ml in the control and patient groups’ plasma, and 223.992 ng/ml in the PF of the patient group. An increase in sST2 level was detected in the patient group compared to the control group ( P <0.001). The sST2 expression in plasma was higher in the patient group than in the control group. Additionally, sST2 was more expressed in the plasma of the patient group than PF ( P <0.001). Conclusion The fact that sST2 was detected for the first time in a high level in PF showed that this biomarker was closely related with the heart and strengthened its potential to be used as a biomarker. Therefore, sST2 can contribute to the understanding of the pathophysiology of coronary artery disease.

Triple Cascade Quantum-Strip for Heart Failure Point-of-Care Testing

“…In particular, among the five subjects, patient#11 without heart disease had the lowest serum ST2 level, indicating good cardiac status, while the rest of them suffering from coronary atherosclerotic disease had relatively high ST2 levels. According to research, , the serum ST2 level also could give significant information in asymptomatic individuals with coronary artery disease. In patients with stable coronary artery disease, patients with a serum ST2 value of 24.6 ng/mL had long-term mortality, and those above this value had a 2-fold increased risk of death .…”

DPP3: From biomarker to therapeutic target of cardiovascular diseases

“…Recent studies have reported that known biomarkers such as brain natriuretic peptide (BNP) ( 116 ), N-terminal pro-brain natriuretic peptide (NT-proBNP) ( 117 ), growth stimulation expressed gene 2 (ST2) ( 118 ), and troponin ( 119 ) are not of high value in the prediction of cardiogenic shock, while DPP3 as a recently discovered biomarker is attracting researchers' attention ( 77 , 120 ). To elucidate the effects of circulating DPP3 on cardiac function and renal hemodynamics, Benjamin Deniau and colleagues ( 121 ) measured the circulatory level of DPP3 of 174 patients with acute heart failure and found that a high level of circulatory DPP3 was associated with short-term mortality risk and severe organ dysfunction.…”

COVID-19 Associated Inflammatory Pathways

“…The serum sST2 in patients with COVID-19 was significantly increased and negatively correlated with the number of CD4+ and CD8+T lymphocytes. During the disease's progression, serum sST2 levels continued to rise in severe cases that did not survive [10].…”